Personalised medicine aims to tailor treatments to individual patients based on their predicted response or risk of disease. It can avoid unnecessary treatment, improve drug-development success rates and reduce costs. Biomarker-based assays have become key tools in the personalised medicine arsenal. A companion diagnostic compares the effect of a medicinal product in patients with and without a particular biomarker.
The UK has deposited the document required to apply the Protocol to the Agreement on a Unified Patent Court on provisional application (PPA) with the depository for the UPC Agreement.
The Intellectual Property (Unjustified Threats) Bill received Royal Assent on 27 April 2017. This creates the Intellectual Property (Unjustified Threats) Act 2017 which is expected to come in to force in October 2017.